How HCA Stock’s Quiet Compounding Changes The Growth Story

With shares lagging and revenue growth slowing, the market seems to be missing the powerful engine driving HCA’s per-share earnings higher.

It’s not hard to see why investors are cautious on HCA Healthcare (HCA) stock. The shares have lagged the broader market, trading well off their 52-week highs. The narrative is one of slowing growth, with recent results hit by a mild respiratory season and winter storms that dampened patient volumes.

But focusing only on the headline sales number may miss the most important part of the story. There is one metric that reveals a more powerful, and perhaps underappreciated, dynamic at play: the significant gap between how fast the business is growing and how fast shareholder earnings are compounding.

The Real Growth Isn’t In The Top Line

Over the past three years, HCA’s revenue grew at a compound annual rate of 7.9%. A solid, but not spectacular, figure. Over that same period, its earnings per share compounded at 13.3% a year.

That nearly six-percentage-point gap is the centerpiece of the bullish thesis. It’s evidence of a company that doesn’t need heroic top-line growth to create meaningful value for its owners. The business is engineered to turn modest sales growth into much faster per-share profit growth. And it does so with two straightforward, powerful levers.

How Two Levers Magnify Profits

First, the company is getting more profitable on each dollar of sales. HCA’s operating margin has risen in each of the last two years, climbing from 14.6% two years ago, to 15.1% a year ago, to 15.7% over the last twelve months. That steady expansion means profits are growing faster than revenue, a classic sign of operational discipline.

Second, HCA is consistently shrinking its share count. By steadily buying back its own stock, the company has reduced the number of outstanding shares by about 19.3% over the past three years. This means that a growing profit pool is being divided among fewer and fewer slices, concentrating the value for the remaining shareholders.

An Answer To The Market’s Biggest Fear?

This brings us back to the main worry hanging over the stock: slowing growth. Skeptics rightly point out that revenue growth over the last year has moderated to 6.7%. But the company’s ability to compound earnings per share at a much faster rate is a direct answer to that concern. It shows the business has durable ways to reward investors that are not entirely dependent on a booming top line.

The stock’s current valuation appears to give little credit for this quiet compounding. With a trailing price-to-earnings multiple of 12.7, the stock is trading in the lower half of its 10-year range of 7.6 to 17.6. That suggests a market focused on the risks, perhaps overlooking the powerful mechanics of HCA’s earnings engine.

For HCA Healthcare, beyond watching for revenue to re-accelerate, the key is whether management can keep that gap between earnings and sales growth wide open.

Where An Edge Like This Belongs

Here is the honest takeaway. The case above is strong, but the skill that surfaced it, reading past a frightening headline to the quality of what is underneath, is the rare and time-consuming part of investing. Spotting one edge is hard enough; spotting them consistently, across dozens of names, is a different order of effort.

That effort is what the Trefis High Quality (HQ) Portfolio exists to provide: a focused set of 30 quality businesses, researched the same way and re-balanced with discipline, so being wrong on any one name barely moves the whole. No single stock is a sure thing, which is exactly why a rules-based basket beats betting the farm on one, and this one has outpaced a benchmark that combines all major indices – the S&P 500, S&P Mid-cap, and Russell 2000. For investors who view mechanics like these as an edge, a disciplined, rules-based approach to quality warrants consideration.